Abstract Background Orthotopic liver transplantation (OLT) in patients with inflammatory bowel disease (IBD) represents a special patient population with high heterogeneity. The management of IBD in liver transplant recipients is challenging due to the need to balance immunosuppressive therapy, IBD flares and graft survival. Therefore, detailed analysis of clinical parameters is essential to better understand outcomes and optimize management strategies in this unique cohort. Methods This monocentric, retrospective analysis included IBD patients with concomitant OLT at our tertiary referral center. We reviewed the local database for incident cases from January 2013 to December 2023. Identified patients have been evaluated based on demographic data, detailed IBD and OLT history, complications (including re-OLT), and overall survival. Results This study included 126 IBD patients with OLT, with a mean age of 37.3 years at transplantation and a mean age of 28.2 years at IBD diagnosis. The majority of patients were male (68.3%), and ulcerative colitis (UC) was the most common diagnosis (86.5%), followed by Crohn’s disease (CD) (11.9%). Among UC patients, 79.8% had extensive colitis (E3), while in CD patients, the distribution was 40% L1, 26.7% L2, and 33.3% L3. The most common indication for OLT in this cohort was PSC (74.6%), followed by PSC/AIH variants (13.5%). Before OLT, 42.1% of patients were treated with corticosteroids, while 56.8% continued steroid treatment after OLT. Aminosalicylates were prescribed to 69.2% of patients pre-OLT, but only 49.6% continued this treatment post-OLT. 90.4% of patients did not require advanced therapies after OLT, though biologics like vedolizumab and ustekinumab were used in a small subset. 27.2% of patients required re-OLT, with UC being the most prevalent IBD entity for re-transplantation (82.4%). Colectomy after OLT was performed in 12.7% of patients, and it was associated with a higher likelihood of re-OLT (p = 0.04; OR: 3.1; 95% CI: 1.06-9.1), while post-OLT 5-ASA therapy was associated with a reduced likelihood of re-OLT (p = 0.03; OR: 0.4; 95% CI: 0.17-0.9). Overall mortality post-OLT was 26.2%. A COX-Regression analysis further revealed significant associations with overall mortality and e. g. age at IBD diagnosis (p < 0.01; HR: 1.07; 95% CI: 1.04-1.11), male sex (p = 0.045; HR: 2.95; 95% CI: 1.02-8.52), steroid use post-OLT (p=0.04: HR: 2.6, CI: 1.06-6.43) and PSC (p=0.04: HR: 0.3, CI: 0.11-0.95). Conclusion To the best of our knowledge, this is the largest monocentric IBD OLT cohort. We identified 5-ASA and steroid therapy as modifiable risk factors for re-OLT and mortality in IBD patients after OLT. Further validation of these findings in a larger multicentric setting is recommended.
Read full abstract